IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 826 days ago
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 377 days ago
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 560 days ago
CAC 40 Moderately Higher; Thales Up Sharply

CAC 40 Moderately Higher; Thales Up Sharply

French stocks are up in positive territory Monday morning, led by gains in defense shares, amid prospects of increased defense spending following European leaders echoing recent views of the U.K. about increasing spending for the sector.
RTTNews | 5h 12min ago
DAX Rise 1.25% As Defense Stocks Rally

DAX Rise 1.25% As Defense Stocks Rally

German stocks are up firmly in positive territory Monday morning, outperforming peers from the region, thanks to hectic buying in defense stocks on reports the Christian Democratic Union (CDU) and their prospective coalition partner/partners, are considering setting up two special funds for defense and infrastructure investments.
RTTNews | 5h 50min ago
U.S. Dollar Falls Amid U.S. Fed Rate Cut Prospect

U.S. Dollar Falls Amid U.S. Fed Rate Cut Prospect

The U.S. dollar weakened against other major currencies in the Asian session on Monday, amid prospects of the U.S. Fed cutting interest rates earlier as it is feared that the U.S. trade war may hurt global growth, worsen inflation and possibly spark recessions in some countries. Traders also picked up stocks at a bargain after the recent slump in the markets.
RTTNews | 7h 26min ago
Asian Shares Mostly Higher On Improved China Data

Asian Shares Mostly Higher On Improved China Data

Asian stocks advanced on Monday as new PMI data suggested China's manufacturing had a solid start to 2025 and European leaders pledged to assemble a "coalition of the willing" to develop a plan for ending Ukraine's war with Russia.
RTTNews | 7h 43min ago